[go: up one dir, main page]

ITMI20020269A1 - USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY - Google Patents

USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY

Info

Publication number
ITMI20020269A1
ITMI20020269A1 IT2002MI000269A ITMI20020269A ITMI20020269A1 IT MI20020269 A1 ITMI20020269 A1 IT MI20020269A1 IT 2002MI000269 A IT2002MI000269 A IT 2002MI000269A IT MI20020269 A ITMI20020269 A IT MI20020269A IT MI20020269 A1 ITMI20020269 A1 IT MI20020269A1
Authority
IT
Italy
Prior art keywords
steres
omega
patients
acid ethyl
heart insufficiency
Prior art date
Application number
IT2002MI000269A
Other languages
Italian (it)
Original Assignee
Victorix Assets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victorix Assets Ltd filed Critical Victorix Assets Ltd
Priority to IT2002MI000269A priority Critical patent/ITMI20020269A1/en
Publication of ITMI20020269A0 publication Critical patent/ITMI20020269A0/en
Priority to AU2003210210A priority patent/AU2003210210A1/en
Priority to EP03739455A priority patent/EP1474125A1/en
Priority to PCT/EP2003/001108 priority patent/WO2003068216A1/en
Publication of ITMI20020269A1 publication Critical patent/ITMI20020269A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IT2002MI000269A 2002-02-12 2002-02-12 USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY ITMI20020269A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT2002MI000269A ITMI20020269A1 (en) 2002-02-12 2002-02-12 USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
AU2003210210A AU2003210210A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
EP03739455A EP1474125A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
PCT/EP2003/001108 WO2003068216A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI000269A ITMI20020269A1 (en) 2002-02-12 2002-02-12 USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY

Publications (2)

Publication Number Publication Date
ITMI20020269A0 ITMI20020269A0 (en) 2002-02-12
ITMI20020269A1 true ITMI20020269A1 (en) 2003-08-12

Family

ID=11449201

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI000269A ITMI20020269A1 (en) 2002-02-12 2002-02-12 USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY

Country Status (4)

Country Link
EP (1) EP1474125A1 (en)
AU (1) AU2003210210A1 (en)
IT (1) ITMI20020269A1 (en)
WO (1) WO2003068216A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20022511A1 (en) * 2002-11-26 2004-05-27 Victorix Assets Ltd USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
ES2277557B1 (en) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
PL1962825T3 (en) * 2005-12-21 2014-09-30 Brudy Tech S L Use of dha for treating a pathology associated with cellular oxidative damage
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
PT3037089T (en) 2009-02-10 2020-03-04 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
KR102118478B1 (en) * 2009-03-09 2020-06-04 바스프 에이에스 Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (en) 2009-06-15 2018-06-01 阿马里纳制药公司 Triglycerides, composition and method without increasing LDL-C levels are reduced in the object of associated Statins therapy
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc LOW-ERUCATION COMPOSITION AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASE IN A SUBJECT HAVING FISH ALLERGY / HYPERSENSITIVITY
EP2674157A4 (en) 2011-02-07 2014-07-09 Mochida Pharm Co Ltd Therapeutic agent for diastolic congestive heart failure
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
JP6307442B2 (en) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject
SMT202500326T1 (en) 2012-06-29 2025-11-10 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal stroke in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3700518A4 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
CN114980973A (en) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 Method for reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
EP4326244A4 (en) 2021-04-21 2025-03-19 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
ATE305810T1 (en) * 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con PHARMACEUTICAL COMPOSITION CONTAINING FATTY ACID WHICH IS AT LEAST 80 Wt. CONTAINS EPA AND DHA
ITMI20010129A1 (en) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE

Also Published As

Publication number Publication date
AU2003210210A1 (en) 2003-09-04
WO2003068216A1 (en) 2003-08-21
ITMI20020269A0 (en) 2002-02-12
EP1474125A1 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
ITMI20020269A1 (en) USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
NO20033304D0 (en) Essential N-3 fatty acids in cardiac insufficiency and heart failure therapy
NO20023879D0 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
IS8233A (en) Propionic acid derivatives useful in the treatment of fatty diseases
DE60217176D1 (en) MULTICULAR BALLOON CATHETER FOR REDUCING DAMAGE TO COATED EXPANDABLE MEDICAL IMPLANTS
AU2003213768A1 (en) Use of benzimidazole analogs in the treatment of cell proliferation
ATE315388T1 (en) THERAPEUTIC COMBINATIONS OF FATTY ACIDS
ITRM20030210A1 (en) PROSTHESIS TO BE USED IN THE PROLASSO SURGICAL THERAPY
AU2003217759A8 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
IS7444A (en) Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases
ITMI20022511A1 (en) USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
ITRM20020014A0 (en) DERIVATIVES OF A-PHENYLTHIOCARBOXYLIC AND A-PHENYLOXYCARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF
NO20030295D0 (en) Use of derivatives of valproic acid and 2-valproic acid amides for the treatment of manners in bipolar disorders
DE602004022034D1 (en) PREPARATION OF CONJUGATED LINOLIC ACIDS AND LINOLIC ACID SALTS
ITMI20030647A1 (en) DEVICE FOR THE TREATMENT OF BLOOD IN EXTRACORPOREA CIRCULATION
ITMI20021552A1 (en) DEVICE FOR THE TREATMENT OF BLOOD IN EXTRA-BODY CIRCUIT
ITMI20020115A0 (en) USE OF ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN PATIENTS WITH HEART FAILURE
ITRM20030178A1 (en) USE OF L-CARNITINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
IS7804A (en) Indole is useful in the treatment of androgen receptor-related diseases
EP1578980A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN 213P1F11 FOR USE IN THE TREATMENT AND DETECTION OF CANCER
ITMI20020750A0 (en) ESSENTIAL FATTY ACIDS IN THE TREATMENT OF HEART DISEASE
NO20031080L (en) Fatty acid analogues for the treatment of proliferative diseases
ITBO20020022A0 (en) PHARMACEUTICAL COMPOSITIONS FOR SKIN CARE AND THEIR USE
ITMI20021205A0 (en) USE OF PROTEINS FOR THE TREATMENT OF LEISHMANIASIS
NO20011107D0 (en) Stent coated with fatty acid analogues